Validation and evaluation of a common biomarker in human cancers sera protein detected by a monoclonal antibody UNIVmAb

Manjunath, D.; Kumaraswamy, Sunil B; Venkatakrishniah, Shashidhar Aladhi; Appaiah, Hitesh; Thomas, Anil; Banerjee, Shib D.

doi:10.1186/s13104-019-4780-4

Cited by 2 publications

(2 citation statements)

References 21 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The validation phase also requires a number of patients defined through power analysis, and the number of biomarkers to be tested must also be considered. This can range from tens to thousands of patient samples, which are analyzed by immunological assays such as ELISA, immunohistochemistry, dot blot, Western blot, and others [ 13 , 15 , 66 , 99 , 100 ].…”

Section: Biomarker’s Development Phasementioning

confidence: 99%

“…Blood is the most commonly used medium in clinical analysis and an important biofluid for researching diagnostic and prognostic biomarkers of human diseases [ 13 , 15 , 16 , 17 , 66 , 90 , 92 , 93 , 95 , 97 , 100 , 101 ]. An innumerable number of variables can have an immeasurable impact on the results of the analyses ( Figure 2 ).…”

Section: Preanalytical Variables: Sample Preparation Challengesmentioning

confidence: 99%

See 1 more Smart Citation

Challenges and Opportunities in Clinical Diagnostic Routine of Envenomation Using Blood Plasma Proteomics

Cavalcante

Almeida

Moraes

et al. 2023

Toxins

View full text Add to dashboard Cite

Specific and sensitive tools for the diagnosis and monitoring of accidents by venomous animals are urgently needed. Several diagnostic and monitoring assays have been developed; however, they have not yet reached the clinic. This has resulted in late diagnoses, which represents one of the main causes of progression from mild to severe disease. Human blood is a protein-rich biological fluid that is routinely collected in hospital settings for diagnostic purposes, which can translate research progress from the laboratory to the clinic. Although it is a limited view, blood plasma proteins provide information about the clinical picture of envenomation. Proteome disturbances in response to envenomation by venomous animals have been identified, allowing mass spectrometry (MS)-based plasma proteomics to emerge as a tool in a range of clinical diagnostics and disease management that can be applied to cases of venomous animal envenomation. Here, we provide a review of the state of the art on routine laboratory diagnoses of envenomation by snakes, scorpions, bees, and spiders, as well as a review of the diagnostic methods and the challenges encountered. We present the state of the art on clinical proteomics as the standardization of procedures to be performed within and between research laboratories, favoring a more excellent peptide coverage of candidate proteins for biomarkers. Therefore, the selection of a sample type and method of preparation should be very specific and based on the discovery of biomarkers in specific approaches. However, the sample collection protocol (e.g., collection tube type) and the processing procedure of the sample (e.g., clotting temperature, time allowed for clotting, and anticoagulant used) are equally important to eliminate any bias.

show abstract

Section: Biomarker’s Development Phasementioning

confidence: 99%

Section: Preanalytical Variables: Sample Preparation Challengesmentioning

confidence: 99%

Challenges and Opportunities in Clinical Diagnostic Routine of Envenomation Using Blood Plasma Proteomics

Cavalcante

Almeida

Moraes

et al. 2023

Toxins

View full text Add to dashboard Cite

show abstract

UNIVmAb reactive albumin associated hyaladherin as a potential biomarker for colorectal cancer

Kolapalli

Kumaraswamy

Mortha

et al. 2021

CBM

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common cancer; cancer biomarker discovery is important for disease detection and management. It is known that hyaluronic acid and its receptors are ubiquitously expressed in almost all human tissues. Earlier we have shown that a monoclonal antibody H11B2C2, presently known as UNIVmAb, reactive hyaladherin expressed in multiple human cancers mainly using immunohistochemistry. However, the nature of the antigen and its sequence homology are not known. In the current study, a comprehensive investigation was performed to explore the nature of the antigen and its homology using both biochemical and proteomic analysis. Our results showed that UNIVmAb reactive 57 kDa antigen was overexpressed in advanced grade colorectal cancer tissues compared to benign and its adjacent benign tissues. Biochemical investigations including biotinylated hyaluronic acid-pulldown, Immunoprecipitation, HA-oligo competition experiments confirmed that the UNIVmAb reactive 57 kDa antigen is a member of hyaladherin. Further Proteomic analysis showed that the antigen has homology with IGHG1 (Igγ-1 chain C region), IGg superfamily, and is associated with human serum albumin.

show abstract

Validation and evaluation of a common biomarker in human cancers sera protein detected by a monoclonal antibody UNIVmAb

Cited by 2 publications

References 21 publications

Challenges and Opportunities in Clinical Diagnostic Routine of Envenomation Using Blood Plasma Proteomics

Challenges and Opportunities in Clinical Diagnostic Routine of Envenomation Using Blood Plasma Proteomics

UNIVmAb reactive albumin associated hyaladherin as a potential biomarker for colorectal cancer

Contact Info

Product

Resources

About